Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs

Infectious Agents and Cancer

Arpaporn Arnamwong¹  Waraphorn Krongthong¹  Wandee Udomchaiprasertkul¹  Gaidganok Sornsamdang¹  Siriporn Saeloo¹  Chantanee Taepisitpong¹  Narongchai Teerayathanakul¹  Chirayu Auewarakul²  Natacha Phoolcharoen³  Thaniya Sricharunrat¹  Narongrit Sritana¹  Chulabhorn Mahidol²  Nuttavut Kantathavorn³ 

[1] Chulabhorn Hospital, Bangkok, Thailand;Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand;Gynecologic Oncology Unit, Chulabhorn Hospital, 54 Kamphaengphet 6 Road, Laksi, Bangkok 10210, Thailand

关键词: Thailand;    Cervical cytology;    HPV genotypes;    Cancer screening;    Cervical cancer;   

Others  :  1133665
DOI  :  10.1186/s13027-015-0001-5

 received in 2014-11-22, accepted in 2015-01-30,  发布年份 2015

【 摘 要 】

Background

Cervical cancer is the major cause of morbidity and mortality in Thai women. Nevertheless, the preventive strategy such as HPV vaccination program has not been implemented at the national level. This study explored the HPV prevalence and genotypic distribution in a large cohort of Thai women.

Methods

A hospital-based cervical cancer screening program at Chulabhorn Hospital, Bangkok and a population-based screening program at a rural Pathum Thani Province were conducted using liquid-based cytology and HPV genotyping.

Results

Of 5906 women aged 20–70 years, Pap smear was abnormal in 4.9% and the overall HPV prevalence was 15.1%, with 6.4% high-risk (HR), 3.5% probable high-risk (PR), and 8.4% low-risk (LR) HPV. The prevalence and genotypic distribution were not significantly different between the two cohorts. Among HR-HPV genotypes, HPV52 was the most frequent (1.6%), followed by HPV16 (1.4%), HPV51 (0.9%), HPV58 (0.8%), HPV18 (0.6%), and HPV39 (0.6%). Among LR-HPV genotypes, HPV72 and HPV62 were the most frequent while HPV6 and HPV11 were rare. HPV infection was found to be proportionately high in young women, aged 20–30 years (25%) and decreasing with age (11% in women aged >50). The more severe abnormal cytology results, the higher positivity of HR-HPV infection was observed.

Conclusions

In conclusion, HPV52, HPV16, and HPV51 were identified as the most common HR-HPV genotypes in Thai women. This study contributes genotypic evidence that should be essential for the development of appropriate HPV vaccination program as part of Thailand’s cervical cancer prevention strategies.

【 授权许可】

   
2015 Kantathavorn et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 [Internet]. International Agency for Research on Cancer: Lyon, France; 2013. Available from: http://globocan.iarc.fr, accessed on 18/11/2014.
• [2]Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-65.
• [3]Bosch FX, de Sanjose S: Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J Natl Cancer Inst Monogr 2003, 31:3-13.
• [4]Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-9.
• [5]Chin'ombe N, Sebata NL, Ruhanya V, Matarira HT: Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe. Infect Agent Cancer 2014, 9:16. BioMed Central Full Text
• [6]Ermel A, Ramogola-Masire D, Zetola N, Tong Y, Qadadri B, Azar MM, et al.: Invasive cervical cancers from women living in the United States or Botswana: differences in human papillomavirus type distribution. Infect Agent Cancer 2014, 9:22. BioMed Central Full Text
• [7]Franco EL, Harper DM: Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005, 23:2388-94.
• [8]de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al.: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-9.
• [9]Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-99.
• [10]Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
• [11]Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM: Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128:927-35.
• [12]Apgar BS, Zoschnick L, Wright TC Jr: The Bethesda system terminology. Am Fam Physician 2001, 2003(68):1992-8.
• [13]Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
• [14]Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
• [15]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.: WHO international agency for research on cancer monograph working group: a review of human carcinogens–part B: biological agents. Lancet Oncol 2009, 10:321-2.
• [16]Schiffman M, Clifford G, Buonaguro FM: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009, 4:8. BioMed Central Full Text
• [17]Ralston Howe E, Li Z, McGlennen RC, Hellerstedt WL, Downs LS Jr. Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol. 2009;200:245 e1-7.
• [18]Dickson EL, Vogel RI, Bliss RL, Downs LS Jr: Multiple-type human papillomavirus (HPV) infections: a cross-sectional analysis of the prevalence of specific types in 309,000 women referred for HPV testing at the time of cervical cytology. Int J Gynecol Cancer 2013, 23:1295-302.
• [19]Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L: Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol 2009, 81:529-35.
• [20]Anderson L, O'Rorke M, Jamison J, Wilson R, Gavin A: HPV Working Group members: Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis. J Med Virol 2013, 85:295-308.
• [21]Ucakar V, Poljak M, Klavs I: Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study. Vaccine 2012, 30:116-20.
• [22]Swangvaree SS, Kongkaew P, Rugsuj P, Saruk O: Prevalence of high-risk human papillomavirus infection and cytologic results in Thailand. Asian Pac J Cancer Prev 2010, 11:1465-8.
• [23]Chansaenroj J, Lurchachaiwong W, Termrungruanglert W, Tresukosol D, Niruthisard S, Trivijitsilp P, et al.: Prevalence and genotypes of human papillomavirus among Thai women. Asian Pac J Cancer Prev 2010, 11:117-22.
• [24]Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, et al.: Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003, 187:1246-56.
• [25]Inoue M, Sakaguchi J, Sasagawa T, Tango M: The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 2006, 16:1007-13.
• [26]Li H, Zhang J, Chen Z, Zhou B, Tan Y: Prevalence of human papillomavirus genotypes among women in Hunan province, China. Eur J Obstet Gynecol Reprod Biol 2013, 170:202-5.
• [27]Parkin DM, Louie KS, Clifford G: Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine 2008, 26(Suppl 12):M1-16.
• [28]Maehama T: Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterine cervix. Infect Dis Obstet Gynecol 2005, 13:77-80.
• [29]Sriamporn S, Snijders PJ, Pientong C, Pisani P, Ekalaksananan T, Meijer CJ, et al.: Human papillomavirus and cervical cancer from a prospective study in Khon Kaen, Northeast Thailand. Int J Gynecol Cancer 2006, 16:266-9.
• [30]Aggarwal R, Gupta S, Nijhawan R, Suri V, Kaur A, Bhasin V, et al.: Prevalence of high–risk human papillomavirus infections in women with benign cervical cytology: a hospital based study from North India. Indian J Cancer 2006, 43:110-6.
• [31]Arora R, Kumar A, Prusty BK, Kailash U, Batra S, Das BC: Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur J Obstet Gynecol Reprod Biol 2005, 121:104-9.
• [32]Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, et al.: Human papillomavirus infection in Shanxi Province, People’s Republic of China: a population-based study. Br J Cancer 2006, 95:96-101.
• [33]Zhao FH, Zhu FC, Chen W, Li J, Hu YM, Hong Y, et al.: Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial. Int J Cancer 2014, 135:2604-11.
• [34]Siriaunkgul S, Suwiwat S, Settakorn J, Khunamornpong S, Tungsinmunkong K, Boonthum A, et al.: HPV genotyping in cervical cancer in Northern Thailand: adapting the linear array HPV assay for use on paraffin-embedded tissue. Gynecol Oncol 2008, 108:555-60.
• [35]Chinchai T, Chansaenroj J, Swangvaree S, Junyangdikul P, Poovorawan Y: Prevalence of human papillomavirus genotypes in cervical cancer. Int J Gynecol Cancer 2012, 22:1063-8.
• [36]Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-88.
• [37]Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al.: HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-94.
• [38]Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al.: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009, 101:1612-23.